Conventional, single-slice helical computed tomography (CT) allows for scanning the majority of the liver during the critical portal venous phase. This is often referred to as the ‘optimal temporal window’. In general, it occurs following a 70-s scan delay and is coincidental with the maximal delivery of contrast via the portal vein that provides 80% of the hepatic blood supply. This yields maximal conspicuity between low attenuation lesions and the enhanced normal liver parenchyma. This provides optimal imaging for the vast majority of hepatic metastases. Most importantly, these scanners, when compared to conventional non-helical scanners, avoid impinging upon the ‘equilibrium’ phase where tumors can become isodense/invisible. Helical CT also allows scanning during the arterial phase for detection of hypervascular lesions but was limited in its ability to scan effectively in multiple phases necessary for detection of hypervascular metastases.With the introduction of multislice CT, imaging speed has increased significantly especially with the introduction of 8- and 16-detector systems and will continue to increase in the future volumetric CT. This provides a number of important gains that are discussed in detail.

Author

Paul M Silverman

Contact Details

Corresponding address:
Paul M Silverman, Department of Radiology, University of Texas M. D. Anderson Cancer
Center, Houston, TX, USA

Reference

ICIS Cancer Imaging Volume 4 Special Iissue B
DOI: 10.1102/1470-7330.2004.0058

Date Posted

3 January 2005

Print PDF

Size

4.73 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	18 seconds
ADSL 512Kb/s (Broadband):	1 minute 15 seconds
64 Kb/s (ISDN):	10 minutes 5 seconds
33.3 Kb/s (Typical Modem):	19 minutes 22 seconds

Screen PDF

Size

626.65 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	2 seconds
ADSL 512Kb/s (Broadband):	9 seconds
64 Kb/s (ISDN):	1 minute 18 seconds
33.3 Kb/s (Typical Modem):	2 minutes 30 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.